N-benzyl-6-(4-phenylbutoxy)hexan-1-amine

We are N-benzyl-6-(4-phenylbutoxy)hexan-1-amine CAS:97664-55-6 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:   N-benzyl-6-(4-phenylbutoxy)hexan-1-amine
CAS.NO:97664-55-6
Synonyms:
N-[6-(4-phenylbutoxy)hexyl]benzenemethanamine
6-Benzylamino-1-(4'-phenylbutoxy)hexane
6-N-benzylamino-1-(4'-phenylbutoxy)hexane
benzyl(6-(4-pheylbutoxy)hexyl)amine
N-benzyl-6-(4-phenylbutoxy)hexylamine

Molecular Formula: C23H33NO
Molecular Weight:  339.51400

Physical and Chemical Properties:
Density:0.979 g/cm3
Boiling point: 467.238ºC at 760 mmHg
Melting point: /
Flash point:207.26ºC
Refractive index: /

Specification:
Appearance: Off-white powder
Purity:≥98.0%

Packing:
 25kg  cardboard drum or according to customer specified requirements
Storage:
Store in a tightly closed container. Store in a cool, dry, well-ventilated area away from incompatible substances.
Application: 
 Intermediates of Salmeterol CAS:89365-50-4.

Related News: We are pleased that intravenous rigosertib will be made compliantly available to suitable patients with higher-risk MDS through their physicians in designated countries.dodecyl prop-2-enoate The company’s product reserves are rich, with more than one hundred varieties in various categories from intermediates to APIs. At present, the grays and anti-hepatitis C series intermediates are steadily advancing, which will ensure future growth.5-nitrovanilina CAS:6635-20-7 In the first round of nationwide implement of the program, in September, multinationals including Sanofi and Eli Lilly managed to cut some prices low enough to levels close to those offered by local generic makers.4-Ethoxy-3-(1-methyl-7-oxo-3-propyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-5-yl)benzenesulfonyl chloride It is understood that at present, the industry competition for global characteristic APIs has shown a development trend of vertical integration, and the number of mergers and acquisitions between pharmaceutical manufacturers and API manufacturers is increasing.The company’s proprietary induced pluripotent stem cell (iPSC) product platform enables mass production of off-the-shelf, engineered, homogeneous cell products that can be administered with multiple doses to deliver more effective pharmacologic activity, including in combination with cycles of other cancer treatments.